Format

Send to

Choose Destination
Curr Opin Mol Ther. 2007 Jun;9(3):299-304.

Drug evaluation: CP-751871, a human antibody against type I insulin-like growth factor receptor for the potential treatment of cancer.

Author information

1
Department of Medicine, Division of Hematology, Oncology and Transplantation, University of Minnesota Cancer Center, MMC 806, 420 Delaware Street SE, Minneapolis, MN 55455, USA. sachd003@umn.edu

Erratum in

  • Curr Opin Mol Ther. 2007 Aug;9(4):411.

Abstract

Several phase II trials of CP-751871 are currently underway, including a phase Ib/II [corrected] trial of CP-751871 in combination with paclitaxel and carboplatin in patients with advanced NSCLC, a phase II trial of CP-751871 in combination with docetaxel and prednisone in patients with hormone-refractory prostate cancer, and a phase II trial of CP-751871 in combination with exemestane in hormone receptor positive advanced breast cancer [corrected].

PMID:
17608029
[Indexed for MEDLINE]

Supplemental Content

Loading ...
Support Center